Quent Capital’s AbbVie ABBV Stock Holding History

Quent Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41M	Buy	9,570 +565	+6%	+$122K	0.15%	87
2026 Q1	$1.96M	Sell	9,005 -564	-6%	-$125K	0.14%	91
2025 Q4	$2.19M	Buy	9,569 +172	+2%	+$39.2K	0.16%	86
2025 Q3	$2.18M	Sell	9,397 -82	-0.9%	-$16.7K	0.18%	71
2025 Q2	$1.76M	Buy	9,479 +84	+0.9%	+$15.6K	0.17%	73
2025 Q1	$1.97M	Buy	9,395 +507	+6%	+$98.6K	0.21%	67
2024 Q4	$1.58M	Buy	8,888 +22	+0.2%	+$4.04K	0.16%	69
2024 Q3	$1.75M	Buy	8,866 +99	+1%	+$18.5K	0.18%	74
2024 Q2	$1.5M	Buy	8,767 +27	+0.3%	+$4.47K	0.17%	74
2024 Q1	$1.59M	Buy	8,740 +283	+3%	+$48.8K	0.19%	70
2023 Q4	$1.31M	Buy	8,457 +806	+11%	+$118K	0.18%	75
2023 Q3	$1.14M	Sell	7,651 -19	-0.2%	-$2.79K	0.18%	72
2023 Q2	$1.03M	Buy	7,670 +45	+0.6%	+$6.6K	0.16%	78
2023 Q1	$1.21M	Buy	7,625 +137	+2%	+$20.9K	0.21%	64
2022 Q4	$1.21M	Buy	7,488 +1,291	+21%	+$198K	0.22%	65
2022 Q3	$832K	Buy	6,197 +933	+18%	+$134K	0.17%	77
2022 Q2	$806K	Buy	5,264 +315	+6%	+$48.1K	0.17%	74
2022 Q1	$802K	Buy	4,949 +876	+22%	+$127K	0.15%	93
2021 Q4	$552K	Buy	+4,073	New	+$481K	0.12%	146

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Quent Capital's ABBV Position: Q2 2026 in Review

Quent Capital increased its AbbVie (ABBV) stake by 6.3% in Q2 2026, buying an estimated $122K and bringing the position to 9,570 shares worth $2.41M. The position accounts for 0.15% of the portfolio, ranked #87.

Quent Capital first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Quent Capital held 9,570 shares of AbbVie worth $2.41M as of Q2 2026.
Quent Capital bought 565 AbbVie shares in Q2 2026, an estimated $122K.
AbbVie made up 0.15% of Quent Capital's portfolio in Q2 2026, its #87 holding.
Quent Capital first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.